In the case of Cyclin-D1, immunohistochemical studies showed that 19.51% of patients with pancreatic cancer did not show tissue expression for this component, while in the case of patients with low/medium expression, it was 46.34%. This evidence concerns the gene CCND1 and familial pancreatic carcinoma.